{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016372","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.965481+00:00","generated_at":"2026-05-29T01:46:12.989876+00:00","sec_items":["3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025","bullets":["Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.","Preliminary Phase 1 data for XTX301 (IL-12) in 34 patients: no DLTs, no Grade 4/5 AEs, sustained IFN-gamma signaling.","No measurable activated XTX301 in peripheral circulation; majority of AEs Grade 1/2 (flu-like, CRS, transaminitis).","Cash runway guidance updated: existing cash + equivalents expected to fund operations into Q3 2025.","Initial Phase 2 data for vilastobart (XTX101) + atezolizumab in MSS CRC to be presented at ASCO GI (Jan 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016372","json":"https://secwatch.observer/filing/0001558370-24-016372.json","markdown":"https://secwatch.observer/filing/0001558370-24-016372.md","text":"https://secwatch.observer/filing/0001558370-24-016372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/0001558370-24-016372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/xlo-20241218x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:46:12.989876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}